# Nuclide record fpi-2265 (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/fpi-2265/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "fpi-2265" ;
  schema:name "FPI-2265"@en ;
  schema:alternateName "Ac225-PSMA I&T"@en ;
  schema:description "FPI-2265 is an experimental radioligand therapy from Fusion Pharmaceuticals in phase 2 trials for prostate cancer, aimed at PSMA."@en ;
  schema:url <https://nuclide.cc/drugs/fpi-2265/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=FPI-2265> ;
  nuclide:status "phase-2" ;
  nuclide:tag "pipeline", "ctgov-ingest" ;
  nuclide:modality "radioligand" ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/> ;
  nuclide:trials <https://nuclide.cc/trials/nct07611110/>, <https://nuclide.cc/trials/nct05219500/>, <https://nuclide.cc/trials/nct07590934/>, <https://nuclide.cc/trials/nct06909825/> .